Glimepirid Hexal

Glimepirid Hexal is an oral antidiabetic medication that contains the active ingredient glimepiride, a sulfonylurea class drug. It is marketed in the European Union and is available by prescription only. The product works by stimulating insulin release from pancreatic beta‑cells, helping to lower blood glucose levels in adults with type 2 diabetes mellitus.

Glimepirid Hexal is prescribed for the management of type 2 diabetes mellitus when diet, exercise, and other oral agents are insufficient. It may be used as monotherapy or in combination with other antidiabetic drugs.

- Improves glycaemic control in adults with type 2 diabetes - Can be added to metformin when monotherapy does not achieve target glucose - May be combined with DPP‑4 inhibitors for enhanced effect - Used when lifestyle measures alone fail to maintain HbA1c goals - Suitable for patients who require an oral insulin secretagogue

Glimepirid Hexal may cause a range of side effects, some of which are more frequent than others. Patients should be aware of both common and serious reactions.

Common: - Mild hypoglycaemia, especially with missed meals - Nausea or gastrointestinal discomfort - Headache or dizziness - Weight gain due to increased insulin activity - Skin rash or mild itching

Serious: - Severe hypoglycaemia leading to loss of consciousness - Allergic reactions such as angio‑edema or anaphylaxis - Hematologic abnormalities like leukopenia or thrombocytopenia

Before starting Glimepirid Hexal, certain health considerations should be reviewed to minimise risk.

- Assess renal and hepatic function, as impairment may affect drug clearance - Use cautiously in elderly patients who are more prone to hypoglycaemia - Monitor blood glucose regularly to adjust dose appropriately - Avoid use during pregnancy unless benefits outweigh risks; data are limited - Discontinue if signs of severe hypoglycaemia or allergic reaction appear - Review concomitant medications that may potentiate insulin secretion

Glimepirid Hexal can interact with several drug classes, influencing its efficacy or safety profile.

Avoid: - Other sulfonylureas or insulin secretagogues that increase hypoglycaemia risk - Strong CYP2C9 inhibitors (e.g., fluconazole) that raise glimepiride levels - MAO‑B inhibitors that may potentiate hypoglycaemic effects

Use with caution: - Beta‑blockers, which can mask hypoglycaemia symptoms - Thiazide diuretics that may elevate blood glucose - Corticosteroids, which can counteract glucose‑lowering action - Alcohol, as it can enhance hypoglycaemic episodes